Gerasimos Filippatos
European Journal of Heart Failure · 2005–2022
A researcher in the Science corpus: 51 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Who trusts Gerasimos Filippatos
- aguda y crónica (in Cardiology and Cardiovascular Medicine)
Papers from Gerasimos Filippatos's perspective
Ordered by how strongly the researchers Gerasimos Filippatos trusts endorse each paper. Same corpus, a different order for every researcher.
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
- Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. (New England Journal of Medicine)
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. (The Lancet)
- Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. (New England Journal of Medicine)
- Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. (Journal of the American College of Cardiology)
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (Journal of the American Medical Association (JAMA))
- Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. (Archives of Internal Medicine)
- Angiotensin-neprilysin inhibition versus enalapril in heart failure. (New England Journal of Medicine)
- Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. (Journal of the American College of Cardiology)
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) (Circulation)
Their papers
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. (2019) — 3,193 citations
- Mitochondrial function as a therapeutic target in heart failure (2016) — 649 citations
- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. (2022) — 784 citations
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) — 3,081 citations
- Universal Definition and Classification of Heart Failure. (2021) — 845 citations
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (2021) — 5,988 citations
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. (2021) — 1,134 citations
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure (2021) — 1,522 citations
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. (2020) — 1,916 citations
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. (2020) — 1,064 citations
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2020) — 3,699 citations
- The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology (2019) — 962 citations
- How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). (2019) — 1,457 citations
- Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations (2019) — 671 citations
- Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology (2018) — 742 citations
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018) — 597 citations
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017) — 1,596 citations
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017) — 2,083 citations
- Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry (2017) — 821 citations
- Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology (2016) — 1,088 citations